

STENTYS Reports 81% Year-over-Year Growth in Fourth-Quarter 2015 Revenues

Annual Revenues of €6.1 million, up 59% over prior year

PRINCETON, N.J. and PARIS - January 13, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its revenues for the fourth quarter and full year 2015.

- 2015 annual and fourth-quarter revenues*

€ thousand	Annual			Quarterly		
	2015	2014	% change	Q4 2015	Q4 2014	% change
Revenues	6,102.06	3,851.10	+58.5%	1,880.46	1,038.70	+81.0%

* Figures reviewed by the statutory auditors

STENTYS recorded revenues of €1.9 million in the final quarter of 2015, an increase of 81% compared with the same quarter of 2014. Over 2015 as a whole, revenues were up 59% and totaled €6.1 million. This number confirms the Xposition® stent's growing adoption among cardiologists since its launch during the 2nd quarter of 2015. Over the 2nd half of the year, regional tenders awarded in the Middle East also contributed to the Company's growth. MiStent® SES commercialization continued as a controlled launch and is now active in 8 countries, with revenues of €283k during the 2015 fiscal year.

- Cash position

At December 31, 2015, STENTYS had a cash position of €10.7 million, vs. €18.6 million at December 31, 2014.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, explains: "The continued growth acceleration over all four quarters of 2015 confirms that the Xposition drug eluting stent perfectly meets the needs of cardiologists: the product is now more efficacious and easier to use. In 2016, our ambition is to keep delivering a high growth rate, with the expansion of our geographical coverage, the development of high-potential indications (such as left main coronary artery disease) and the continued controlled launch of the MiStent stent."

- Upcoming financial report

STENTYS expects to publish its financial results for 2015 on March 16, 2016

About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex coronary artery disease. STENTYS' Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company's product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS' commercial network in Europe, the Middle East, Asia and Latin America. **More information is available at www.stentys.com.**

Safe Harbor Statements

This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to

enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 "Risk Factors" of the Company's 2014 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers on July 29, 2015 under number D.15-0807 as such section may be updated from time to time.

STENTYS

Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap

Investor Relations / Strategic Communications
Dusan Oresansky
Tel.: +33 (0)1 44 71 94 93
stentys@newcap.eu

STENTYS is listed on Comp. C of the Euronext Paris market
ISIN: FR0010949404 – Ticker: STNT